Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 17
Submit an article Journal homepage
140
Views
10
CrossRef citations to date
0
Altmetric
Review

Calcineurin inhibitors for the treatment of atopic dermatitis

Jan Ehrchen University of Muenster, Boltzmann-Institute for Cell- and Immunobiology of the Skin, Department of Dermatology, 58, Von Esmarch Str, D-48149 Muenster, Germany +49 251 83 57481; +49 251 83 56522; [email protected]
,
Cord Sunderkötter University of Muenster, Boltzmann-Institute for Cell- and Immunobiology of the Skin, Department of Dermatology, 58, Von Esmarch Str, D-48149 Muenster, Germany +49 251 83 57481; +49 251 83 56522; [email protected]
,
Thomas Luger University of Muenster, Boltzmann-Institute for Cell- and Immunobiology of the Skin, Department of Dermatology, 58, Von Esmarch Str, D-48149 Muenster, Germany +49 251 83 57481; +49 251 83 56522; [email protected]
&
Martin Steinhoff University of Muenster, Boltzmann-Institute for Cell- and Immunobiology of the Skin, Department of Dermatology, 58, Von Esmarch Str, D-48149 Muenster, Germany +49 251 83 57481; +49 251 83 56522; [email protected]
Pages 3009-3023 | Published online: 04 Nov 2008

Bibliography

  • Elias PM, Steinhoff M. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol 2008;128:1067-70
  • Bieber T. Atopic dermatitis. N Engl J Med 2008;358:1483-94
  • Singh S, Gupta A, Pandey SS, et al. Tachyphylaxis to histamine-induced wheal suppression by topical 0.05% clobetasol propionate in normal versus croton oil-induced dermatitic skin. Dermatol 1996;193:121-3
  • Schoepe S, Schacke H, May E, et al. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 2006;15:406-20
  • Griffiths CE, Katsambas A, Dijkmans BA, et al. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol 2006;155(Suppl 2):1-16
  • Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs 2000;9:69-77
  • Reynolds NJ, Al-Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol 2002;27:555-61
  • Winiski A, Wang S, Schwendinger B, et al. Inhibition of T-cell activation in vitro in human peripheral blood mononuclear cells by pimecrolimus and glucocorticosteroids and combinations thereof. Exp Dermatol 2007;16:699-704
  • Kalthoff FS, Winiski A, Fichtinger P, et al. Differential inhibition of primary versus preactivated T cells by pimecrolimus but not by tacrolimus in vitro Int Arch Allergy Immunol 2007;142:255-64
  • Matsuda S, Shibasaki F, Takehana K, et al. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep 2000;1:428-34
  • Harrison CA, Bastan R, Peirce MJ, et al. Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. Br J Pharmacol 2007;150:509-18
  • Stander S, Stander H, Seeliger S, et al. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol 2007;156:1020-6
  • Lee YH, Lee YR, Im SA, et al. Calcineurin inhibitors block MHC-restricted antigen presentation in vivo J Immunol 2007;179:5711-6
  • Al-Daraji WI, Grant KR, Ryan K, et al. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol 2002;118:779-88
  • Reynolds NJ, Voorhees JJ, Fisher GJ. Cyclosporin A inhibits 12-O-tetradecanoyl-phorbol-13-acetate-induced cutaneous inflammation in severe combined immunodeficient mice that lack functional lymphocytes. Br J Dermatol 1998;139:16-22
  • Krummen MB, Varga G, Steinert M, et al. Effect of pimecrolimus vs. corticosteroids on murine bone marrow-derived dendritic cell differentiation, maturation and function. Exp Dermatol 2006;15:43-50
  • Xhauflaire-Uhoda E, Thirion L, Pierard-Franchimont C, et al. Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis. Dermatol 2007;214:328-32
  • Gollnick H, Luger T, Freytag S, et al. StabiEL: Stabilization of skin condition with Elidel – a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid. J Eur Acad Dermatol Venereol 2008
  • Proksch E, Jensen J, Braeutigam M, et al. Pimecrolimus but not corticosteroid improves the skin barrier in atopic dermatitis. J Invest Dermatol 2008;128:S104
  • Santini MP, Talora C, Seki T, et al. Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci USA 2001;98:9575-80
  • Buchau AS, Schauber J, Hultsch T, et al. Pimecrolimus Enhances TLR2/6-Induced Expression of Antimicrobial Peptides in Keratinocytes. J Invest Dermatol2008; May 22 [Epub ahead of print]
  • Lan CC, Kao YH, Huang SM, et al. FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin. Br J Dermatol 2004;151:679-84
  • Wolff K, Fleming C, Hanifin J, et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate-to-severe atopic dermatitis: a randomized controlled trial. Br J Dermatol 2005;152:1296-303
  • Aspeslet L, Freitag D, Trepanier D, et al. ISA(TX)247: a novel calcineurin inhibitor. Transplant Proc 2001;3:1048-51
  • Papp K, Bissonnette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled Phase III study. Lancet 2008;371(19):1337-42
  • Korfitis C, Gregoriou S, Rallis E, Rigopoulos D. Pimecrolimus versus topical corticosteroids in dermatology. Expert Opin Pharmacother 2007;8:1565-73
  • Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997;337:816-21
  • Paller AS, Lebwohl M, Fleischer AB Jr, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005;52:810-22
  • Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005;330:516
  • Yan J, Chen SL, Wang XL, et al. Meta-analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatr Dermatol 2008;25:117-20
  • Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001;44:S28-38
  • Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000;136:999-1006
  • Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate-to-severe atopic dermatitis. Br J Dermatol 2005;152:1282-9
  • Reitamo S, Rustin M, Harper J, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008
  • Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001;44:S58-64
  • Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005;53:S186-94
  • Beck LA. The efficacy and safety of tacrolimus ointment: a clinical review. J Am Acad Dermatol 2005;53:S165-70
  • Reitamo S, Ortonne JP, Sand C, et al. Long-term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two-year, multicentre, non-comparative study. Acta Derm Venereol 2007;87:406-12
  • Koo JY, Fleischer AB Jr, Abramovits W, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol 2005;53:S195-205
  • Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008;63:742-50
  • Breneman D, Fleischer AB Jr, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol 2008;58(6):990-9
  • Van Leent EJ, Graber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998;134:805-9
  • Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:788-94
  • Eichenfield LF, Thaci D, de PY, et al. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients. Dermatology 2007;215(Suppl 1):3-17
  • Kaufmann R, Folster-Holst R, Hoger P, et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 2004;114:1183-8
  • Leo HL, Bender BG, Leung SB, et al. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. J Allergy Clin Immunol 2004;114:691-3
  • Papp K, Staab D, Harper J, et al. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis.Int J Dermatol 2004;43:978-83
  • Eichenfield LF, Lucky AW, Langley RG, et al. Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome. Int J Dermatol 2005;44:70-5
  • Langley RG, Eichenfield LF, Lucky AW, et al. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Pediatr Dermatol 2008;25:301-7
  • Ashcroft DM, Chen LC, Garside R, et al. Topical pimecrolimus for eczema. Cochrane Database Syst Rev 2007 CD005500
  • Grassberger M, Steinhoff M, Schneider D, et al. Pimecrolimus – an anti-inflammatory drug targeting the skin. Exp Dermatol 2004;13:721-30
  • Meurer M, Lubbe J, Kapp A, Schneider D. The role of pimecrolimus cream 1% (Elidel)) in managing adult atopic eczema. Dermatol 2007;215(Suppl 1):18-26. Epub 2007 Dec 18
  • Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatol 2002;205:271-7
  • Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2
  • Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277-84
  • Papp KA, Werfel T, Folster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005;52:240-6
  • Sunderkotter C, Weiss JM, Bextermoller R, et al. [Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life]. J Dtsch Dermatol Ges 2006;4:301-6
  • Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495-504
  • Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007;157:954-9
  • Zuberbier T, Heinzerling L, Bieber T, et al. Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. Dermatol 2007;215:325-30
  • Zuberbier T, Brautigam M. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. J Eur Acad Dermatol Venereol 2008;22(6):718-21
  • Gollnick H, Kaufmann R, Stough D, et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol 2008;158:1083-93
  • Simon D, Lubbe J, Wuthrich B, et al. Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Analysis of a Swiss cohort. Dermatol 2006;213:313-8
  • Luger TA, Gollnick H, Schwennesen T, et al. Safety and efficacy of pimecrolimus cream 1% in the daily practice: results of a patient self-observation study in patients with atopic dermatitis. J Dtsch Dermatol Ges 2007;5:908-14
  • Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981)–preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001;20:233-41
  • Paul C, Cork M, Rossi AB, et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006;117:e118-28
  • Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003;88:969-73
  • Lakhanpaul M, Davies T, Allen BR, et al. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*. Exp Dermatol 2006;15:138-41
  • Van Leent EJ, De Vries HJ, Ebelin ME, et al. Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year. J Dermatol Treat 2007;18:19-22
  • Staab D, Pariser D, Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis – a multicenter, 3-week, open-label study. Pediatr Dermatol 2005;22:465-71
  • Thaci D, Steinmeyer K, Ebelin ME, et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatol 2003;207:37-42
  • Oji V, Beljan G, Beier K, et al. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 2005;153:1067-8
  • Rubins A, Gutmane R, Valdmane N, et al. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol 2005;125:68-71
  • Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005;124:695-9
  • Soter NA, Fleischer AB Jr, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001;44:S39-46
  • Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001;44:S47-57
  • Beljan G, Traupe H, Metze D, et al. [Comel-Netherton syndrome with bacterial superinfection]. Hautarzt 2003;54:1198-202
  • Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001;137:747-50
  • Beyerler M, Schmid-Grendelmeier P, Hafner J. Significantly elevated systemic levels after occlusive application of topical tacrolimus in atopic dermatitis. Dermatol 2006;212:260-1
  • Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001;44:S65-72
  • Milingou M, Antille C, Sorg O, et al. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Arch Dermatol 2004;140:1542-4
  • Ogunleye T, James WD. Ethanol-induced flushing with topical pimecrolimus use. Dermatitis 2008;19:E1-2
  • Tomi NS, Luger TA. The treatment of atopic dermatitis with topical immunomodulators. Clin Dermatol 2003;21:215-24
  • Remitz A, Kyllonen H, Granlund H, et al. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 2001;107:196-7
  • Hofman T, Cranswick N, Kuna P, et al. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child 2006;91:905-10
  • Stiehm ER, Roberts RL, Kaplan MS, et al. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol 2005;53:S206-13
  • Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005;52:247-53
  • Gradman J, Wolthers OD. Suppressive effects of topical mometasone furoate and tacrolimus on skin prick testing in children. Pediatr Dermatol 2008;25:269-70
  • Mandelin J, Remitz A, Virtanen H, et al. Recall antigen reactions in patients with atopic dermatitis treated with tacrolimus ointment for 1 year. J Allergy Clin Immunol 2008;121:777-9
  • Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998;111:396-8
  • Kyllonen H, Remitz A, Mandelin JM, et al. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004;150:1174-81
  • Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001;144:507-13
  • Ellis D, Jaffe R, Green M, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation 1999;68:997-1003
  • Parrish JA. Immunosuppression, skin cancer, and ultraviolet A radiation. N Engl J Med 2005;353:2712-3
  • Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatol 2007;214:289-95
  • Bieber T, Cork M, Ellis C, et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatol 2005;211:77-8
  • McNeill AM, Koo JY. “Unknown Risks” of non-steroid topical medications for atopic dermatitis. Int J Dermatol 2007;46:656-8
  • Langley RG, Luger TA, Cork MJ, et al. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatol 2007215(Suppl 1):27-44. Epub;%2007 Dec 18.
  • Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007;127:808-16
  • Lerche CM, Philipsen PA, Poulsen T, et al. Topical tacrolimus in combination with simulated solar radiation does not enhance photocarcinogenesis in hairless mice. Exp Dermatol 2008;17:57-62
  • Weischer M, Rocken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol 2007;16:385-93
  • Ring J, Barker J, Behrendt H, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005;19:663-71
  • Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol 2006;15:342-6
  • US National Institutes for Health. ClinicalTrials.gov. Online. Available at: http://clinicaltrials.gov/ct2/home
  • Virtanen H, Remitz A, Malmberg P, et al. Topical tacrolimus in the treatment of atopic dermatitis–does it benefit the airways? A 4-year open follow-up. J Allergy Clin Immunol 2007;120:1464-6
  • Hjelmgren J, Svensson A, Jorgensen ET, et al. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. Br J Dermatol 2007;156:913-21
  • Ellis CN, Drake LA, Prendergast MM, et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol 2003;48:553-63
  • Ellis C, Luger T, Abeck D, et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003;148(Suppl 63):3-10
  • Peserico A, Stadtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 2008;158:801-7
  • Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005;437:369-75

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.